Single-dose psilocybin for a treatment-resistant episode of major depression

BACKGROUND Psilocybin is being studied for use in treatment-resistant depression. METHODS In this phase 2 double-blind trial, we randomly assigned adults with treatment resistant depression to receive a single dose of a proprietary, synthetic formulation of psilocybin at a doseĀ  of 25 mg, 10 mg, or 1 mg (control), along with psychological support. The primary […]

MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults

Background: Suicide is one of the leading causes of death worldwide and rates within the United States have risen over the past two decades. Hence, there is a critical need for novel tools to treat suicidal ideation and related mental health conditions. 3,4-Methylenedioxymethamphetamine (MDMA)/ecstasy and classic psychedelics may be two such tools. Aims: The aim […]